Targeted Screening for Active Tuberculosis –
The Multi-Biomarker Test
The Multi Biomarker Test (MBT) currently developed in ScreenTB will enable lab-independent point-of-care testing for tuberculosis. The patient’s fingerprick blood is inserted into an assay buffer, before applying it to a test strip with 6 test and 6 control lines. The strip is then inserted into a plastic cassette where it is tested for 6 different biomarkers. After 30 minutes, a reader can read out the cassette revealing the patient’s test result.
A prospective pilot study with fresh finger-prick blood already indicated that the assay is well suitable for point-of-care testing. In a small cohort of 29 individuals (12 TB and 17 ORD) using in-sample validation, the 6-marker biosignature test reached a sensitivity/specificity of 100%/71%. The ScreenTB researchers foresee a refinement of the signature for global application and large prospective studies.